Skip to main content


Proteomics - The Key to Novel Biomarkers and Drug Targets

Tuesday, November 16, 2021

12:00 pm - 1:00 pm

About this event

With the steady increase in the coverage and sensitivity of proteomics, we can now visualize an increasing fraction of the proteome in any given disease. A clearer understanding of the protein networks altered in a disease paves the path to novel disease biomarkers (diagnostic biomarkers, prognostic biomarkers, predictive biomarkers, pharmacokinetic drug response biomarkers, etc.) and therapeutic targets. Our recent findings on lupus nephritis and cancer will be discussed.

About the Speaker

Chandra Mohan, M.D., Ph.D., is the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering in the UH Cullen College of Engineering.

Following his medical training in Pathology and Rheumatology at the National University of Singapore and the Singapore General Hospital in Singapore, Dr. Mohan undertook his doctoral thesis work focusing on the cellular immunology of lupus at Tufts University, Boston. His post-doctoral training focused on the genetic analysis of murine lupus.

As an independent investigator, his laboratory’s research efforts have concentrated on elucidating the cellular, molecular and genetic players leading to murine lupus nephritis, with corresponding translational studies in human lupus nephritis. His more recent work has focused on translating findings from basic biology toward the early diagnosis of end-organ involvement in autoimmune diseases. Dr. Mohan’s ongoing studies are aimed at tapping leads from proteomic platforms to mine new biomarkers and targets in chronic rheumatic diseases and selected cancers, and to apply the latest bioengineering technologies to advance the management of these ailments.

In his recent tenure as an endowed Professor of Medicine at UT Southwestern Medical Center, Dr. Mohan held the McGee Chair in Arthritis Research and the Walter and Helen Bader Professorship in Autoimmunity. Dr. Mohan is an elected member of the American Society of Clinical Investigation and the Henry Kunkel Society. He has published around 250 articles, largely in the area of autoimmunity and biomarkers.